Alnylam Pharmaceuticals, Inc.: Alnylam Submits CTA Application for ALN-APP, an Investigational RNAi Therapeutic for the Treatment of Alzheimer's Disease and Cerebral Amyloid Angiopathy
- Company Expects to Initiate a Phase 1 Study in Early-Onset Alzheimer's Disease in Early 2022, with Initial Human Data at or Around Year-End 2022 - - ALN-APP Marks the Industry's First-Ever RNAi
United Kingdom Christine Regan Lindenboom Josh Brodsky Tim Mooney Regeneron Pharmaceuticals Company Expects To Initiatea Phase
Source: finanznachrichten.de